Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples